AndreakosE, SalagianniM, GalaniIE, KoltsidaO. 2017. Interferon-lambdas: front-line guardians of immunity and homeostasis in the respiratory tract. Front Immunol, 8:1232.
2.
AnsariMA, Pedergnana VC LCI, MagriA, Von DelftA, BonsallD, ChaturvediN, BarthaI, SmithD, NicholsonG, McVeanG, TrebesA, PiazzaP, FellayJ, CookeG, FosterGR, ConsortiumS-H, HudsonE, McLauchlanJ, SimmondsP, BowdenR, KlenermanP, BarnesE, SpencerCCA. 2017. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet, 49(5):666–673.
3.
KelemenLE, LawrensonK, TyrerJ, LiQ, LeeJM, SeoJH, PhelanCM, BeesleyJ, ChenX, SpindlerTJ, AbenKK, Anton-CulverH, AntonenkovaN, Australian CancerS, Australian Ovarian Cancer StudyG, Ovarian Cancer AssociationConsortium. 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet, 47(8):888–897.
4.
LazearHM, NiceTJ, DiamondMS. 2015. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity, 43(1):15–28.
5.
LeeS, BaldridgeMT. 2017. Interferon-lambda: a potent regulator of intestinal viral infections. Front Immunol, 8:749.
6.
MinasTZ, TangW, SmithCJ, OnabajoOO, ObajemuA, DorseyTH, JordanSV, ObadiOM, RyanBM, Prokunina-OlssonL, LoffredoCA, AmbsS. 2018. IFNL4-DeltaG is associated with prostate cancer among men at increased risk of sexually transmitted infections. Commun Biol, 1:191.
7.
NCI. 2018. Interferon lambda: disease impact and therapeutic potential. Bethesda,MD.
8.
OdendallC, VoakAA, KaganJC. 2017. Type III IFNs are commonly induced by bacteria-sensing TLRs and reinforce epithelial barriers during infection. J Immunol, 199(9):3270–3279.
9.
OnabajoOO, Porter-GillP, PaquinA, RaoN, LiuL, TangW, BrandN, Prokunina-OlssonL. 2015. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells. J Interferon Cytokine Res, 35(11):888–900.
10.
Prokunina-OlssonL, MuchmoreB, TangW, PfeifferRM, ParkH, DickensheetsH, HergottD, Porter-GillP, MumyA, KohaarI, ChenS, BrandN, TarwayM, LiuL, SheikhF, AstemborskiJ, BonkovskyHL, EdlinBR, HowellCD, MorganTR, ThomasDL, RehermannB, DonnellyRP, O'BrienTR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 45(2):164–171.
11.
WellsAI, CoyneCB. 2018. Type III interferons in antiviral defenses at barrier surfaces. Trends Immunol, 39(10):848–858.
12.
ZanoniI, GranucciF, BroggiA. 2017. Interferon (IFN)-lambda Takes the Helm: immunomodulatory roles of type III IFNs. Front Immunol, 8:1661.
